Mga Batayang Estadistika
| CIK | 1075880 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kazia Therapeutics Limited - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 1, 2025 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of July 31, 2025, is between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHERE |
|
| August 1, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| August 1, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| August 1, 2025 |
EX-4.1 Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITED Number of Ordinary Shares: , represented by American Depositary Shares Issue Date: August, 2025 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Hold |
|
| August 1, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| August 1, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW |
|
| August 1, 2025 |
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market SYDNEY, August 1, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIPE). Pursuant to |
|
| July 25, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| July 25, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT July 25, 2025 Rodman & Renshaw LLC 600 Lexington Avenue, 32nd Floor New York, NY 10022 Ladies and Gentlemen: Kazia Therapeutics Limited ACN 063 259 754, an Australian public company limited by shares (the “Company”), confirms its agreement (this “Agreement”) with Rodman & Renshaw LLC and its successors and permitted assigns (the “Manager”) as follows: 1 |
|
| July 25, 2025 |
Up to $1,906,196 American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-281937 PROSPECTUS SUPPLEMENT (to Prospectus dated September 12, 2024) Up to $1,906,196 American Depositary Shares representing Ordinary Shares We have entered into an At The Market Offering Agreement, or the Sales Agreement, with Rodman & Renshaw LLC, or Rodman & Renshaw, dated July 25, 2025, relating to the sale of Amer |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| July 25, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| July 25, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| July 9, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| July 9, 2025 |
Exhibit 99.1 Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizuma |
|
| July 9, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| July 9, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| July 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| June 11, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| June 11, 2025 |
Exhibit 99.1 Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib’s Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC) Sydney, Australia – 11 June 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publication of transformat |
|
| June 11, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| June 11, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a p |
|
| June 11, 2025 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| June 10, 2025 |
Exhibit 99.1 Kazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2024 Kazia Therapeutics Limited Directors’ report 31 December 2024 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated |
|
| June 10, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| June 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June , 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| June 10, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| June 10, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| June 5, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| June 5, 2025 |
1,770,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| June 5, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| June 5, 2025 |
EX-99.1 2 d832779dex991.htm EX-99.1 Exhibit 99.1 Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast cancer Sydney, Australia – June 5, 2025. Kazia T |
|
| June 5, 2025 |
6-K 1 d832779d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Bara |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 ( |
|
| May 28, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| May 28, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| May 28, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of o |
|
| May 15, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 1,770,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| May 15, 2025 |
95,111 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 95,111 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a par |
|
| May 15, 2025 |
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| May 15, 2025 |
Exhibit 99.1 15 May 2025 Kazia Therapeutics Highlights Recent Progress and Provides Business Update Awarded research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the therapeutic potential of paxalisib as a treatment for Parkinson’s disease (PD) Launched clinical trial ev |
|
| May 15, 2025 |
274,666 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 274,666 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part of |
|
| April 15, 2025 |
475,555 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a pa |
|
| April 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| April 15, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| April 15, 2025 |
FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| March 31, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| March 31, 2025 |
475,555 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| March 31, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “Prospectus”), which forms a part |
|
| March 31, 2025 |
Exhibit 99.1 31 March 2025 Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil Sydney, March 31, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or “the Company”), an oncology-focused drug development c |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| March 13, 2025 |
Exhibit 99.1 Exhibit 99.1 2024 ANNUAL REPORT Contents 2 4 6 Chairman and Key About GBM CEO’s Letter Milestones 8 12 Environment, Financial Society & Reports Governance ii ASX:KZA | NASDAQ:KZIA Chairman and CEO’s The journey of a young biotech Letter company is often circuitous, but we have nevertheless continued to make great progress in the past year. We Key have two first-class drug candidates M |
|
| February 21, 2025 |
424B3 1 d910443d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2025) 1,373,333 American Depositary Shares representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2025 (the “P |
|
| February 20, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| February 20, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| February 20, 2025 |
Exhibit 99.1 20 February 2025 Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson’s Disease Sydney, February 20, 2025 – Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or “the Company”), an oncology-focused drug development company, today announced a research |
|
| February 20, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| February 5, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-284606 PROSPECTUS 1,373,333 American Depositary Shares Representing 137,333,300 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 1,373,333 American Depositary Shares, or the Offered ADSs, with each Am |
|
| February 3, 2025 |
Exhibit 99.1 A Diversified Oncology Drug Development Company Kazia Corporate Overview January 2025 NASDAQ: KZIA | X: @KaziaTx Forward Looking Statements This presentation contains forward -looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar w |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| February 3, 2025 |
CORRESP 1 filename1.htm February 3, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Kazia Therapeutics Limited Acceleration Request for Registration Statement on Form F-1 File No. 333-284606 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), K |
|
| January 30, 2025 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-1 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 137,333,300 $0. |
|
| January 30, 2025 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a |
|
| January 30, 2025 |
EX-99.1 Exhibit 99.1 Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer Sydney; 30 January 2025: Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxali |
|
| January 30, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 F-1 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. |
|
| January 30, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| January 16, 2025 |
Exhibit 1 AGREEMENT OF JOINT FILING The undersigned hereby agree that they are filing jointly, pursuant to Rule 13d-1 of the Securities Exchange Act of 1934, the Schedule 13G dated on or about January 16, 2025, containing the information required by Schedule 13G, for the American Depositary Shares of Kazia Therapeutics Limited held by Alumni Capital LP, a Delaware limited partnership, and with respect to Alumni Capital GP LLC, the manager of Alumni Capital, and Ashkan Mapar, the manager of Alumni Capital GP LLC, such other holdings as may be reported therein. |
|
| January 13, 2025 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| January 13, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| January 13, 2025 |
Exhibit 10.2 PLACEMENT AGENCY AGREEMENT January 10, 2025 Kazia Therapeutics Limited Three International Towers Level 24, 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Dear Mr. Friend: This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Kazia Therapeutics Limited, a company organized in Australia (the “Company”), pursuant to wh |
|
| January 13, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-281937 PROSPECTUS SUPPLEMENT (To prospectus dated September 12, 2024) 553,440 American Depositary Shares representing 55,344,000 Ordinary Shares Pre-funded Warrants to Purchase up to 779,893 American Depositary Shares Up to 779,893 American Depositary Shares representing 77,989,300 Ordinary Shares issuable upon exercise of the |
|
| January 13, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of January 10, 2025, is between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, s |
|
| January 13, 2025 |
Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITED Number of American Depositary Shares: Issue Date: , 2025 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subje |
|
| January 13, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| January 13, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| January 13, 2025 |
Exhibit 4.4 LOCK-UP AGREEMENT January 10, 2025 Re: Securities Purchase Agreement, dated as of January 10, 2025, between Kazia Therapeutics Limited (the “Company”) and the purchasers signatory thereto (the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Securities Purchase Agreement (t |
|
| January 13, 2025 |
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering Exhibit 99.1 Kazia Therapeutics Announces $2.0 Million Registered Direct Offering SYDNEY, Australia, January 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the Company’s American Depositary Sh |
|
| January 10, 2025 |
Kazia Therapeutics Limited Up to $1,734,081 American Depositary Shares representing Ordinary Shares PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated September 12, 2024 and Prospectus dated September 12, 2024) Filed pursuant to Rule 424(b)(5) Registration No. |
|
| December 31, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| December 31, 2024 |
Exhibit 99.1 31 December 2024 Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA Sydney, December 31, 2024–Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food |
|
| December 31, 2024 |
8,850,000 American Depositary Shares representing Ordinary Shares Kazia Therapeutics Limited Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| December 11, 2024 |
EX-99.1 Exhibit 99.1 11 December 2024 Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium Sydney, December 11, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development, announced that data from two abstracts wil |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 475,555 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part of |
|
| December 11, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated December 2, 2024) 8,850,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 2, 2024 (the “Prospectus”), which forms a part |
|
| December 3, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS 475,555 American Depositary Shares representing 47,555,500 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 475,555 American Depositary Shares, or the Offered ADSs, with each America |
|
| December 3, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS Up to 7,500,000 American Depositary Shares Representing 750,000,000 Ordinary Shares Warrant to Purchase Up to 1,350,000 American Depositary Shares Up to 1,350,000 American Depositary Shares Representing 135,000,000 Ordinary Shares Issuable Upon Exercise of the Warrant Kazia Therapeutics Limited This prospectu |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 27, 2024 |
As filed with the Securities and Exchange Commission on November 27, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 27, 2024 Registration No. |
|
| November 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We have issued our report dated October 14, 2022 with respect to the consolidated financial statements included in the Annual Report of Kazia Therapeutics Limited on Form 20-F, prior to the restatement due to the correction of an error, as described in Note 4, and a reclassification as described in Note 5, for the year ended Jun |
|
| November 15, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-281937 and 333-276091) of Kazia Therapeutics Limited (the Company) of our report dated November 15, 2024, relating to the consolidated financial statements which appears in this Annual Report on Form 20-F. Our report contains |
|
| November 15, 2024 |
Exhibit 11.1 Securities Trading Policy Kazia Therapeutics Limited (ACN 063 259 754) (Company) Approved by the Board on 24 February 2021 Table of contents 1. Purpose 3 2. Insider trading prohibitions in the Corporations Act 4 3. No dealing in Prohibited Periods 6 4. Exceptional circumstances 8 5. Permitted dealings 9 6. Further restrictions 11 7. Confidential Information 12 8. Review and publicatio |
|
| November 15, 2024 |
EX-13.1 Exhibit 13.1 Certification of the Principal Executive Officer and the Principal Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John Fri |
|
| November 15, 2024 |
EX-12.1 Exhibit 12.1 Certification of the Principal Executive Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, John Friend, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2024 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statement of a m |
|
| November 15, 2024 |
EX-12.2 Exhibit 12.2 Certification of the Principal Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Jeffrey Bonacorda, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2024 (“Report”) of Kazia Therapeutics Limited (the “Company”); 2. Based on my knowledge, this Report does not contain any untrue statement |
|
| November 15, 2024 |
Offer of Employment with Kazia Therapeutics Exhibit 4.21 April 25, 2024 Jeffrey Bonacorda [***] Dear Jeff, Offer of Employment with Kazia Therapeutics On behalf of Kazia Therapeutics, Inc, I am pleased to offer you the position of Vice President Finance and Controller. We look forward to welcoming you as a colleague. The terms of the position are as set forth below. Position Particulars. Your position, place of work, and commencement date w |
|
| November 15, 2024 |
KAZIA THERAPEUTICS LIMITED COMPENSATION RECOVERY POLICY Adopted as of October 24, 2023 Exhibit 97.1 KAZIA THERAPEUTICS LIMITED COMPENSATION RECOVERY POLICY Adopted as of October 24, 2023 Kazia Therapeutics Limited, a public company under the Australian Corporations Act 2001 (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously |
|
| November 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| November 15, 2024 |
DESCRIPTION OF AMERICAN DEPOSITARY SHARES Exhibit 2.2 DESCRIPTION OF AMERICAN DEPOSITARY SHARES The Bank of New York Mellon, as depositary, has registered and delivered American Depositary Shares, also referred to as ADSs. Each ADS represents 100 ordinary shares (or a right to receive 100 ordinary shares) deposited with HSBC Bank Australia Limited, as custodian for the depositary. Each ADS may also represent any other securities, cash or |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| November 12, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| November 12, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| November 4, 2024 |
Exhibit 99.1 4 November 2024 Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme Company and FDA to meet in December to discuss potential pathways to registration of paxalisib in glioblastoma multiforme (GBM) Company updates to corporate presentation and participation in upcoming |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 4, 2024 |
Exhibit 99.2 A Diversified Oncology Drug Development Company Kazia Corporate Overview November 2024 NASDAQ: KZIA | X: @KaziaTx Forward Looking Statements This presentation contains forward -looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| October 15, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
Exhibit 99.1 2 October 2024 Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66thAnnual Meeting Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial resp |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| October 2, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| September 23, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 23, 2024 |
EX-99.1 Exhibit 99.1 23 September 2024 Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium Sydney, September 23, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) |
|
| September 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| September 13, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part of our |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| September 13, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| September 13, 2024 |
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER EX-99.1 Exhibit 99.1 12 September 2024 KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER Sydney, September 12, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia’s foremost cancer research centres, to obtain an exclusive licen |
|
| September 10, 2024 |
September 10, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 5, 2024 |
As filed with the Securities and Exchange Commission on September 4, 2024. F-3 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2024. |
|
| September 5, 2024 |
AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT September 4, 2024 Exhibit 1.3 AMENDMENT NO. 1 TO EQUITY DISTRIBUTION AGREEMENT September 4, 2024 This Amendment No. 1 (“Amendment No. 1”) amends that certain Equity Distribution Agreement, dated April 22, 2022 (the “Agreement”), by and between Kazia Therapeutics Limited ACN 063 259 754 (the “Company”) and Oppenheimer & Co. Inc., as sales agent (the “Sales Agent”). Defined terms used herein and not otherwise defined |
|
| September 5, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Kazia Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering of Securities: Fees to Be Paid Equity Ordinary Shares, par value $0. |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kazia Therapeutics Limited (Name of Issuer) American Depository Shares (Title of Class of Securities) 48669G105 (CUSIP Number) ALUMNI CAPITAL LP 80 S.W. 8TH Street Suite 2000 Miami, FL 33131 Telephone: (202) 599-5679 (Name, Address and Telephone Number o |
|
| July 10, 2024 |
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma EX-99.1 Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylated patients with glioblastoma Sydney, July 10, 2024 — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug developm |
|
| July 10, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| July 10, 2024 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a |
|
| July 10, 2024 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS SUPPLEMENT (to Prospectus dated June 24, 2024) 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June 24, 2024 (the “Prospectus”), which forms a part o |
|
| July 10, 2024 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated May 29, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part o |
|
| July 2, 2024 |
SC 13G 1 ea0208855-13galumnikazia.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kazia Therapeutics Limited (Name of Issuer) American Depository Shares (Title of Class of Securities) 48669G105 (CUSIP Number) ALUMNI CAPITAL LP 80 S.W. 8TH Street Suite 2000 Miami, FL 33131 Telephone: (2 |
|
| June 28, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280447 PROSPECTUS Up to 1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by Armistice Capital Master Fund Ltd. or its affiliates (collectively referred to herein as “Armistice Capital” or the “Selling Shareholder”), from time to time o |
|
| June 26, 2024 |
June 26, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 25, 2024 |
As filed with the Securities and Exchange Commission on June 24, 2024 F-1 Table of Contents As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. |
|
| June 25, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-1 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 11,000,000 $0. |
|
| June 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS SUPPLEMENT (to Prospectus dated June 4, 2024) 88,500,000 American Depositary Shares representing 885,000,000 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated May 29, 2024 (the “Prospectus”), which forms a part of our |
|
| June 24, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| June 4, 2024 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-279773 PROSPECTUS Up to 75,000,000 American Depositary Shares Representing 750,000,000 Ordinary Shares Warrant to Purchase Up to 13,500,000 American Depositary Shares Up to 13,500,000 American Depositary Shares Representing 135,000,000 Ordinary Shares Issuable Upon Exercise of the Warrant Kazia Therapeutics Limited This |
|
| May 31, 2024 |
May 31, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 29, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-1 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 885,000,000 $0. |
|
| May 29, 2024 |
As filed with the Securities and Exchange Commission on May 29, 2024 F-1 Table of Contents As filed with the Securities and Exchange Commission on May 29, 2024 Registration No. |
|
| May 23, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 ( |
|
| May 17, 2024 |
Warrant Amendment and New Warrant Issuance Agreement Exhibit 10.1 Warrant Amendment and New Warrant Issuance Agreement This Warrant Amendment and New Warrant Issuance Agreement, dated as of May 17, 2024 (the “Agreement”), is entered into between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and Armistice Capital Master Fund Ltd. (the “Investor”). WHEREAS reference is made to (i) that certain Securiti |
|
| May 17, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 ( |
|
| May 17, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| May 1, 2024 |
424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a |
|
| May 1, 2024 |
EX-99.1 Exhibit 99.1 1 May 2024 KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS Sydney, May 1, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801 Phase 1 clinical trial has concluded that the primary and secondary objec |
|
| May 1, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| April 19, 2024 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (this “Agreement”), dated as of April 19, 2024 (the “Execution Date”), by and between KAZIA THERAPEUTICS LIMITED, a public company incorporated under the laws of Australia (the “Company”), and ALUMNI CAPITAL LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, the C |
|
| April 19, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| April 19, 2024 |
WARRANT KAZIA THERAPEUTICS LIMITED Initial Exercise Date: April ___, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 27, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| March 27, 2024 |
Exhibit 99.1 Kazia Therapeutics Limited ABN 37 063 259 754 Half Yearly Report - 31 December 2023 Kazia Therapeutics Limited Directors’ report 31 December 2023 The directors present their report, together with the financial statements, on the Consolidated entity (referred to hereafter as the ‘Consolidated entity’) consisting of Kazia Therapeutics Limited (referred to hereafter as the ‘Consolidated |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March , 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 200 |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 |
|
| March 26, 2024 |
Exhibit 99.1 21 March 2024 Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases Sydney, March 21, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that it has entered into an exclusive licensing agreement with Sovargen Co., Ltd, a biotechnology company specializin |
|
| February 21, 2024 |
Exhibit 99.1 21 February 2024 Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases Sydney, February 21, 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based |
|
| February 21, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS SUPPLEMENT (to Prospectus dated February 5, 2024) 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February 5, 2024 (the “Prospectus”), which forms a part o |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| February 14, 2024 |
SC 13G 1 armistice-kzia123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kazia Therapeutics Limited (Name of Issuer) American Depositary Shares, each representing ten Ordinary Shares (Title of Class of Securities) 48669G105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of |
|
| February 5, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-276774 PROSPECTUS 4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares Kazia Therapeutics Limited This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of 4,755,556 American Depositary Shares, or the Offered ADSs, with each Ame |
|
| February 2, 2024 |
February 2, 2024 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 31, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-1 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 47,555,560 $0. |
|
| January 31, 2024 |
Exhibit 3.1 Constitution Kazia Therapeutics Limited ACN 063 259 754 Table of contents Definitions and Interpretation 1 1 Definitions 1 2 Interpretation 2 Shares and share capital 4 3 Share capital 4 4 Certificates 6 5 CHESS 8 6 Lien 8 7 Calls 10 8 Forfeiture of Shares 12 9 Transfer of Shares 13 10 Transmission of Shares 15 11 Alteration of capital 16 12 Variation or cancellation of rights 16 13 Re |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 30, 2024 F-1 Table of Contents As filed with the Securities and Exchange Commission on January 30, 2024 Registration No. |
|
| January 18, 2024 |
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS EX-99.1 Exhibit 99.1 PRESS RELEASE 18 January 2024 KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS 18 January 2024 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia’s Board of the Directors (the “Board”) as a Non-Executive Director. Mr. Apple brings more t |
|
| January 18, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| January 12, 2024 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NS |
|
| December 21, 2023 |
December 21, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 15, 2023 |
EX-4.3 Exhibit 4.3 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of October 23, 2023 (the “Effective Date”), is entered into by and between KAZIA THERAPEUTICS LIMITED, a company incorporated under the laws of Australia (“Company”), and Elena Paskalev, her successors and/or assigns (“Investor”). A. Company and Investor are executing and delivering thi |
|
| December 15, 2023 |
As filed with the Securities and Exchange Commission on December 15, 2023. F-3 Table of Contents As filed with the Securities and Exchange Commission on December 15, 2023. |
|
| December 15, 2023 |
EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE Form F-3 (Form Type) Kazia Therapeutics Limited (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (2) Proposed Maximum Offering Price Per Share (4) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, no nominal value per share(1) Rule 457(c) 5,916,970(3) $0. |
|
| December 6, 2023 |
Exhibit 4.1 PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES KAZIA THERAPEUTICS LIMITED Number of American Depositary Shares: Issue Date: , 2023 THIS PREFUNDED WARRANT TO PURCHASE ORDINARY SHARES REPRESENTED BY AMERICAN DEPOSITARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject t |
|
| December 6, 2023 |
Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering Exhibit 99.1 Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering SYDNEY, Australia, December 5, 2023 (PRNewswire) — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused drug development company, today announced the closing of its previously announced purchase and sale of up to an aggregate of 4,444,445 of the Company’s American Deposit |
|
| December 6, 2023 |
LOCK-UP AGREEMENT November 30, 2023 Exhibit 4.4 LOCK-UP AGREEMENT November 30, 2023 Re: Securities Purchase Agreement, dated as of November 30, 2023, between Kazia Therapeutics Limited (the “Company”) and the purchasers signatory thereto (the “Purchasers”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Securities Purchase Agreement |
|
| December 6, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| December 6, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”), dated as of November 30, 2023, is between Kazia Therapeutics Limited, a company incorporated under the laws of Australia (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| December 6, 2023 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT T |
|
| December 4, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-259224 PROSPECTUS SUPPLEMENT (To prospectus dated September 8, 2021) 2,620,000 American Depositary Shares representing 26,620,000 Ordinary Shares Pre-funded Warrants to Purchase up to 1,824,445 American Depositary Shares Up to 1,824,445 American Depositary Shares representing 18,244,450 Ordinary Shares issuable upon exercise o |
|
| December 1, 2023 |
Kazia Therapeutics Announces $2 Million Registered Direct Offering Exhibit 99.1 Kazia Therapeutics Announces $2 Million Registered Direct Offering SYDNEY, Australia, December 1, 2023 (PRNewswire) — Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused drug development company, today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 4,444,445 of the Company’s American De |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 29, 2023 |
Exhibit 99.1 PRESS RELEASE 29 November 2023 KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY 29 November 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has signed a non-binding Letter of Intent (LOI) with an undisclosed biotechno |
|
| November 29, 2023 |
KAZIA THERAPEUTICS LIMITED ABN 37 063 259 754 Exhibit 99.1 KAZIA THERAPEUTICS LIMITED ABN 37 063 259 754 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. THE MATTERS RAISED IN THIS DOCUMENT WILL AFFECT YOUR SHAREHOLDING IN THE COMPANY. YOU ARE ADVISED TO READ THIS DOCUMENT IN ITS ENTIRETY BEFORE THE ANNUAL GENERAL MEETING REFERRED TO BELOW IS CONVENED. IF YOU ARE IN ANY DOUBT ABOUT THE ACTION YOU SHOULD TAKE IN RESPONSE TO TH |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 21, 2023 |
Exhibit 99.1 PRESS RELEASE 21 November 2023 KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING 21 November 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to provide key highlights of the clinical and preclinical paxalisib related presentations given by key thought leaders at t |
|
| November 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 20, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| November 20, 2023 |
KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION EX-99.1 Exhibit 99.1 KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION Sydney, November 20, 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA ) (Kazia or the company) received a deficiency notification from the Listing Qualifications Staff of the Nasdaq Stock Market LLC (Nasdaq), dated November 20, 2023, notifying the company that it is not in compliance with the minimum bid price requireme |
|
| November 15, 2023 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| November 15, 2023 |
Exhibit 99.1 PRESS RELEASE 15 November 2023 KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING 15 November 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that the Society of Neuro-Oncology 2023 Annua |
|
| November 14, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Syd |
|
| November 14, 2023 |
EX-99.1 Exhibit 99.1 PRESS RELEASE 10 November 2023 KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA Sydney, 10 November 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication in Molecular Cancer Therapeutics highlighting paxalisib preclinical da |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2 |
|
| November 1, 2023 |
Exhibit 99.1 ASX RELEASE 01 Nov 2023 KAZIA THERAPEUTICS PROVIDES PRELIMINARY UPDATE FROM ONGOING PHASE 2 STUDY OF PAXALISIB IN PRIMARY CNS LYMPHOMA Sydney, 01 Nov 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide a preliminary update from the ongoing investigator-initiated Phase 2 clinical trial (NCT04906096) evaluating |
|
| October 26, 2023 |
EX-4.23 Exhibit 4.23 Dr John Friend 23 August 2023 By email: [***] Dear John I refer to your appointment as Chief Executive Officer of Kazia Therapeutics Limited effective on 1 May 2023. This letter sets out the amendments to your existing contract of employment as Chief Medical Officer (Existing Contract) dated 20 September 2021, specifically in relation to: • your roles and responsibilities in y |
|
| October 26, 2023 |
U.S. Securities and Exchange Commission EX-15.3 Exhibit 15.3 U.S. Securities and Exchange Commission Office of the Chief Accountant 100 F Street, NE Washington, DC 20549 Grant Thornton Audit Pty Ltd Level 17 383 Kent Street Sydney NSW 2000 Locked Bag Q800 Queen Victoria Building NSW 1230 T +61 2 8297 2400 26 October 2023 Re: Kazia Therapeutics Limited File No. 0-29962 Dear Sir or Madam: We have read the statements made by Kazia Therapeu |
|
| October 26, 2023 |
Consent of Independent Registered Public Accounting Firm EX-15.2 Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We have issued our report dated October 14, 2022 with respect to the consolidated financial statements included in the Annual Report of Kazia Therapeutics Limited on Form 20-F, prior to the restatement due to the correction of an error, as described in Note 4, and a reclassification as described in Note 5, for the year e |
|
| October 26, 2023 |
EX-12.2 Exhibit 12.2 Certification of the Director of Chief Financial Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, Karen Krumeich, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2023 (‘Report’) of Kazia Therapeutics Limited (the ‘Company’); 2. Based on my knowledge, this Report does not contain any untrue state |
|
| October 26, 2023 |
EX-13.1 Exhibit 13.1 Certification of the Chief Executive Officer and the Chief Financial Officer as required by Rule 13a-14(b) of the Securities Exchange Act of 1934 Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), John Friend, Chi |
|
| October 26, 2023 |
Consent of Independent Registered Public Accounting Firm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form F-3 (No.333-259224) of Kazia Therapeutics Limited of our report dated October 26, 2023, related to the consolidated financial statements which appears in the Annual Report to Shareholders on Form 20-F. Our report contains an explana |
|
| October 26, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE |
|
| October 26, 2023 |
EX-12.1 Exhibit 12.1 Certification of the Chief Executive Officer as required by Rule 13a-14(a) of the Securities Exchange Act of 1934 I, John Friend, certify that: 1. I have reviewed this Annual Report on Form 20-F for the fiscal year ended June 30, 2023 (‘Report’) of Kazia Therapeutics Limited (the ‘Company’); 2. Based on my knowledge, this Report does not contain any untrue statement of a mater |
|
| October 23, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydn |
|
| October 23, 2023 |
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY EX-99.1 Exhibit 99.1 ASX RELEASE 23 Oct 2023 KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY Sydney, 23 Oct 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected clinical data from the company’s ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumour |
|
| October 13, 2023 |
Exhibit 99.2 13 October 2023 Dear Shareholder Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) – Voluntary delisting from the ASX Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (Kazia or the Company) has requested and received formal approval from the Australian Securities Exchange (ASX) to be removed from the official list of the ASX (Official List) pursuant to ASX Listing Rule 17.11 (Delisti |
|
| October 13, 2023 |
SHAREHOLDER COMMUNICATION ON THE DE-LISTING PROCESS Exhibit 99.1 ASX RELEASE 13 October 2023 SHAREHOLDER COMMUNICATION ON THE DE-LISTING PROCESS Sydney, 13 October 2023 – Kazia Therapeutics Limited (Kazia or the Company) NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, refers to its Announcement released to the ASX on 11 October 2023 titled “Kazia announces voluntary delisting from ASX”. In accordance with ASX Listing Rule 3.1 |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 11, 2023 |
KAZIA ANNOUNCES VOLUNTARY DELISTING FROM ASX Exhibit 99.1 ASX RELEASE 11 October 2023 KAZIA ANNOUNCES VOLUNTARY DELISTING FROM ASX Sydney, 11 October 2023 - Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (Kazia or the Company), an oncology-focused drug development company, announces its intention to de-list from the Australian Securities Exchange (ASX). Delisting Kazia advises that it has submitted a formal application to the ASX to be re |
|
| October 10, 2023 |
REQUEST FOR VOLUNTARY SUSPENSION Exhibit 99.1 Market Announcement 10 October 2023 Kazia Therapeutics Limited (ASX: KZA) – Suspension from Quotation Description The securities of Kazia Therapeutics Limited (‘KZA’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding the proposed trading solely on Nasdaq and proposed delisting of KZA’s securiti |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 20 |
|
| October 6, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydn |
|
| October 6, 2023 |
Exhibit 99.1 6 October 2023 Ms Lisa Bahn Senior Adviser, Listings Compliance ASX Limited, 20 Bridge Street SYDNEY NSW 2000 REQUEST FOR TRADING HALT BY EMAIL: [email protected] Dear Lisa Kazia Therapeutics Limited- Request for Trading Halt Kazia Therapeutics Limited (ASX : KZA) (Kazia or the Company) requests an immediate halt to the trading of the Company’s securities quoted on the Aus |
|
| September 29, 2023 |
Exhibit 99.1 ASX RELEASE 29 September 2023 KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING Sydney, 29 September 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that data from an ongoing Phase II study (PN |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW |
|
| September 5, 2023 |
EX-99.4 Exhibit 99.4 Kazia Therapeutics Limited Corporate Governance Statement for the year ended 30 June 2023 As at 31 August 2023 The Board is responsible for the corporate governance of Kazia Therapeutics Limited (“Kazia” or “the Company”), including adopting policies and procedures to ensure the Kazia Directors, management and employees fulfil their functions to the standards and in accordance |
|
| September 5, 2023 |
Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations EX-99.3 Exhibit 99.3 Rules 4.7.3 and 4.10.3 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity Kazia Therapeutics Limited ABN/ARBN Financial year ended: 37 063 259 754 30 June 2023 Our corporate governance statement1 for the period above can be found at:2 ☐ These pages of our annual report: X This URL on our website: https://www.kaziatherapeut |
|
| September 5, 2023 |
APPENDIX 4E - PRELIMINARY FINAL REPORT EX-99.2 Exhibit 99.2 APPENDIX 4E - PRELIMINARY FINAL REPORT 1. Company details Name of entity: Kazia Therapeutics Limited ABN: 37 063 259 754 Reporting period: For the year ended 30 June 2023 Previous period: For the year ended 30 June 2022 2. Results for announcement to the market 2022 2023 restated Change Change $ $ $ % Loss from ordinary activities after tax attributable to the owners of Kazia |
|
| September 5, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sy |
|
| September 5, 2023 |
EX-99.1 Exhibit 99.1 ANNUAL REPORT 2023 CONTENTS CHAIRMAN AND CEO’S LETTER KEY MILESTONES INTRODUCTION TO KAZIA’S CEO PIPELINE REVIEW ENVIRONMENT, SOCIETY & GOVERNANCE FINANCIAL REPORTS 2 6 8 10 12 14 ii ASX:KZA | NASDAQ:KZIA The past year has been significant for Kazia Therapeutics, with considerable progress being made across our clinical programs and as a business. We have completed a full port |
|
| August 11, 2023 |
KAZIA THERAPEUTICS ANNOUNCES CHANGE TO BOARD OF DIRECTORS EX-99.1 Exhibit 99.1 ASX RELEASE 11 August 2023 KAZIA THERAPEUTICS ANNOUNCES CHANGE TO BOARD OF DIRECTORS Sydney, 11 August 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced the resignation of Mr. Iain Ross as Chairman and non-executive director effective immediately. The Board of Directors has elected Dr John Friend as Interim Chai |
|
| August 11, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydne |
|
| July 6, 2023 |
EX-99.1 Exhibit 99.1 KAZIA’S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY Sydney, 06 JULY 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that its lead program, paxalisib, has been awarded Fast Tr |
|
| July 6, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| June 26, 2023 |
KAZIA CORPORATE UPDATE AND CORPORATE PRESENTATION Exhibit 99.1 ASX ANNOUNCEMENT 26 June 2023 KAZIA CORPORATE UPDATE AND CORPORATE PRESENTATION Sydney, 26 June 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on key corporate and clinical initiatives and release a new investor presentation. Key points • Dr John Friend completes transition into the CEO role, in |
|
| June 26, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
|
| June 5, 2023 |
EX-99.1 Exhibit 99.1 ASX ANNOUNCEMENT 5 June 2023 KAZIA EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF EBRU DAVIDSON Ms Ebru Davidson appointed as a Non-Executive Director Sydney, 5th June 2023 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announced that Ms Ebru Davidson has been appointed to the Board of Kazia effective today. Kazia’s Chairma |
|
| June 5, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney |
|
| May 1, 2023 |
Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrant’s name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney N |
